MIR155HG is a prognostic biomarker and associated with immune infiltration and immune checkpoint molecules expression in multiple cancers.

MIR155HG is a prognostic biomarker and associated with immune infiltration and immune checkpoint molecules expression in multiple cancers.

Publication date: Sep 30, 2019

In recent years, immune checkpoint inhibitor has achieved remarkable success in multiple cancer treatment. However, how to pre-judge which patients are suitable for immune checkpoint inhibitor is a difficult problem. We use the existing public bioinformatics database to comprehensively analyze the relationship between clinical data of various cancers with immune checkpoint blocking molecules and long non-coding RNAs (lncRNAs), and try to find the potential predictive value of lncRNA for immunotherapy with checkpoint inhibitors. In this study, we found that: (a) high expression of lncRNA MIR155 host gene (MIR155HG) was closely related to better overall survival (OS) in cholangiocarcinoma (CHOL), lung adenocarcinoma (LUAD), and skin cutaneous melanoma (SKCM), and have better disease-free survival (DFS) in CHOL. Meanwhile, the high level of MIR155HG was associated with poorer OS in glioblastoma multiforme (GBM), kidney renal clear cell carcinoma (KIRC), brain lower grade glioma (LGG), and uveal melanoma (UVM). (b) The expression of MIR155HG was significantly correlated with infiltrating levels of immune cells and immune molecules, especially with immune checkpoint molecules such as programmed cell death protein 1 (PD-1), PD-1 ligand 1 (PD-L1), and cytotoxic T lymphocyte-associated antigen 4 (CTLA4) in most kinds of cancers. (c) Detection of clinical CHOL and liver hepatocellular carcinoma tissues confirmed that there was a strong positive correlation between MIR155HG expression and the levels of CTLA4 and PD-L1. MIR155 host gene can be used as a prognostic marker in multiple cancers, and of great value in predicting the curative effect of immune checkpoint inhibitor therapy owing to it is closely related with immune cells infiltration and immune checkpoint molecules expression.

Peng, L., Chen, Z., Chen, Y., Wang, X., and Tang, N. MIR155HG is a prognostic biomarker and associated with immune infiltration and immune checkpoint molecules expression in multiple cancers. 24264. 2019 Cancer Med.

Concepts Keywords
Antigen Immunotherapy
Biomarker Medicine
Brain Medical specialties
Carcinoma Immune system
Cholangiocarcinoma Clinical medicine
Correlation Cancer treatments
CTLA4 Immune checkpoint
Cytotoxic Checkpoint inhibitor
DFS CTLA-4
GBM Immunotherapy
Glioblastoma Multiforme Cancer immunotherapy
Glioma
Hepatocellular Carcinoma
Immune Checkpoint Inhibitor
Immunotherapy
Kidney
Ligand
Liver
LncRNA
LncRNAs
Lymphocyte
Melanoma
Renal
Uveal Melanoma

Semantics

Type Source Name
gene UNIPROT RXFP2
disease DOID hepatocellular carcinoma
disease MESH hepatocellular carcinoma
gene UNIPROT CTLA4
gene UNIPROT CD274
gene UNIPROT PDCD1
gene UNIPROT RPL17
disease DOID uveal melanoma
disease MESH uveal melanoma
disease DOID lower grade glioma
disease DOID renal clear cell carcinoma
disease DOID glioblastoma multiforme
disease MESH glioblastoma multiforme
disease DOID cutaneous melanoma
disease DOID lung adenocarcinoma
disease MESH lung adenocarcinoma
disease DOID cholangiocarcinoma
disease MESH cholangiocarcinoma
drug DRUGBANK Tropicamide
disease DOID cancer
drug DRUGBANK Spinosad
disease MESH cancers

Similar

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *